Aldeyra to Appeal FDA Rejection of Reproxalap via Formal Dispute Resolution Request
ALDX is trading near its 52-week low of $1.07 (12% above the low).
Summary
Aldeyra will formally appeal the FDA's rejection of reproxalap for dry eye disease via a Formal Dispute Resolution Request, with an OND meeting expected in Q4 2026. The company also extended its cash runway into 2029.
Key Events · Product Development and Regulatory · ALDX
-
Formal Dispute Resolution Request Filed
Aldeyra will submit an FDRR to the FDA's Office of New Drugs to appeal the March 16, 2026 Complete Response Letter that denied reproxalap for dry eye disease. Submission and an OND meeting are expected in Q4 2026.
-
Cash Runway Extended to 2029
Based on $45.1M in cash and cash equivalents as of June 30, 2026, Aldeyra extended its projected operational cash runway into 2029, excluding any potential licensing or product revenue from reproxalap.
-
Three Complete Response Letters Received
Aldeyra has received three CRLs for reproxalap. The most recent stated the totality of evidence does not support effectiveness, while the first two recommended an additional clinical trial.
-
Type D Meeting Held September 25
Aldeyra met with the FDA Division of Ophthalmology and Office of Specialty Medicine at a Type D meeting on September 25, 2026, which informed the decision to pursue the FDRR.
Analysis · ALDX · Life Sciences
Aldeyra is escalating its fight with the FDA over reproxalap for dry eye disease. After three Complete Response Letters, the company will submit a Formal Dispute Resolution Request to the Office of New Drugs, with a meeting expected in Q4 2026. This is the company's last clear regulatory avenue for its lead asset, which AbbVie declined to option after the March 2026 rejection. The filing also extends the operational cash runway into 2029, backed by $45.1M in cash as of June 30, 2026 — a meaningful survival signal for a company whose market cap is under $70M.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALDX was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70M. The 52-week trading range was $1.07 to $5.93. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.